IBC's Antibody Engineering & Therapeutics Asia meeting is the leading forum in Asia for bringing together leading scientists and innovators from around the world to discuss novel strategies for antibody, protein and biotherapeutic discovery and development.
BioProcess International China conference is the region's foremost event on bioprocessing and biomanufacturing. It provides you with the most timely information, tools, strategies and techniques that you need to ensure optimal development, from upstream to scale-up to commercialization.
IBC's Cell Therapy Bioprocessing conference has built a reputation of providing a first-rate faculty of participants, who collectively share perspectives and lessons learned from detailed case studies to help you overcome the challenges, develop the strategies and implement the technologies to propel this field towards commercial sustainability.
IBC's Inaugural Immuno-Oncology event provides insights on the latest advances in cancer immunotherapies, this track will focus on overcoming challenges with discovery, development, approval, and product launch. Discussions will cover methods to improve efficacy, potency, and viability of potential therapeutic candidates. Co-located with IBC's 5th Annual Cell Therapy Bioprocessing & Commercialization meeting.
John B Hynes Veterans Memorial Convention Center, Boston, MA
The biopharmaceutical industry's premier event. It is the one place where you know you will meet with the key players in the field. BPI is your industry resource to expand your knowledge with unparalleled access to new, unpublished data and exclusive case studies from companies of all sizes and perspectives. Your attendance prepares your bioprocess operations for success in the highly dynamic market for biologics.
IBC's Antibody Engineering & Therapeutics conference is an invaluable resource for your research programs. Attending these meetings means getting important updates from the early stage work of leading academic researchers and tracking the progress of companies advancing antibody therapeutics through clinical development. Covering both cutting-edge developments in the basic science of antibody engineering and clinical/preclinical updates of therapeutic antibodies in development.